|
Q2 FY2026
As of Jun 30, 2026
|
Q1 FY2026
As of Mar 31, 2026
|
Q4 FY2025
As of Dec 31, 2025
|
Q3 FY2025
As of Sep 30, 2025
|
Q2 FY2025
As of Jun 30, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q3 FY2022
As of Sep 30, 2022
|
Q2 FY2022
As of Jun 30, 2022
|
Q1 FY2022
As of Mar 31, 2022
|
Q4 FY2021
As of Dec 31, 2021
|
Q3 FY2021
As of Sep 30, 2021
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||||||||||
| Current Assets: | ||||||||||||||||||||
| Cash and cash equivalents | ||||||||||||||||||||
| Prepaid and other current assets | ||||||||||||||||||||
| Total Current Assets | ||||||||||||||||||||
| Property, plant and equipment, at cost: | ||||||||||||||||||||
| Property, plant and equipment | ||||||||||||||||||||
| Less: Accumulated depreciation | ||||||||||||||||||||
| Net property, plant and equipment | ||||||||||||||||||||
| Operating lease right-of-use assets | ||||||||||||||||||||
| Finance lease right-of-use assets | ||||||||||||||||||||
| Other long-term assets | ||||||||||||||||||||
| Total Assets | ||||||||||||||||||||
| LIABILITIES AND STOCKHOLDERS' EQUITY | ||||||||||||||||||||
| Current Liabilities: | ||||||||||||||||||||
| Accounts payable | ||||||||||||||||||||
| Convertible Notes | ||||||||||||||||||||
| Series A-1 Convertible Notes | ||||||||||||||||||||
| Series B-1 Convertible Notes | ||||||||||||||||||||
| Total convertible Notes | ||||||||||||||||||||
| Accrued liabilities | ||||||||||||||||||||
| Operating lease liability, current | ||||||||||||||||||||
| Finance lease liability, current | ||||||||||||||||||||
| Total Current Liabilities | ||||||||||||||||||||
| Operating lease liability, net of current | ||||||||||||||||||||
| Finance lease liability, net of current | ||||||||||||||||||||
| Other long-term liabilities | ||||||||||||||||||||
| Total Liabilities | ||||||||||||||||||||
| Stockholders' Equity: | ||||||||||||||||||||
| Common Stock, 400,000,000 shares authorized, $0.001 par value Issued shares - 128,564,994 and 117,989,625, respectively Outstanding shares - 128,564,833 and 117,989,464, respectively | ||||||||||||||||||||
| Paid-in capital | ||||||||||||||||||||
| Accumulated deficit | ||||||||||||||||||||
| Less: Treasury stock (161 shares), at cost | ||||||||||||||||||||
| Total Stockholders' Equity | ||||||||||||||||||||
| Total Liabilities and Stockholders' Equity | ||||||||||||||||||||
Loading...
